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Aim: It has been debated whether different diets are more or less effective in long-term
weight loss success and cardiovascular disease prevention among men and women.
To further explore these questions, the present study evaluated the combined effects of
a high-protein, intermittent fasting, low-calorie diet plan compared with a heart healthy
diet plan during weight loss, and weight loss maintenance on blood lipids and vascular
compliance of obese individuals.
Methods: The experiment involved 40 obese adults (men, n = 21; women, n = 19) and
was divided into two phases: (a) 12-week high-protein, intermittent fasting, low-calorie
weight loss diet comparing men and women (Phase 1) and (b) a 1-year weight
maintenance phase comparing high-protein, intermittent fasting with a heart healthy diet
(Phase 2). Body weight, body mass index (BMI), blood lipids, and arterial compliance
outcomes were assessed at weeks 1 (baseline control), 12 (weight loss), and 64
(12 + 52 week; weight loss maintenance).
Results: At the end of weight loss intervention, concomitant reductions in body weight,
BMI and blood lipids were observed, as well as enhanced arterial compliance. No
sex-specific differences in responses were observed. During phase 2, the high-protein,
intermittent fasting group demonstrated a trend for less regain in BMI, low-density
lipoprotein (LDL), and aortic pulse wave velocity than the heart healthy group.
Conclusion: Our results suggest that a high-protein, intermittent fasting and low-calorie
diet is associated with similar reductions in BMI and blood lipids in obese men and
women. This diet also demonstrated an advantage in minimizing weight regain as well
as enhancing arterial compliance as compared to a heart healthy diet after 1 year.
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INTRODUCTION
In the United States, the prevalence of overweight and
obesity is over 60% in adults (Flegal et al., 2010), which
subsequently contributes to metabolic and cardiovascular
diseases (CVD). Obesity is often understood to coexist
with numerous cardiovascular risk factors (Wilson et al.,
2002), and is associated with multiple inflammatory markers
and cytokines that potentially contribute to the adverse
cardiovascular outcomes in individuals with obesity (Van Gaal
et al., 2006). Men suffer from a higher prevalence of these
disorders than women, indicating that sex-based differences may
play a role in cardiometabolic health (Lönnqvist et al., 1997;
Blaak, 2001). Many short-term weight loss (WL) interventions
are effective at improving cardiovascular/metabolic disease risk
factors [e.g., body fat, total cholesterol (TC), and triglycerides
(TG; Kelishadi et al., 2008; Clifton et al., 2009; Klempel et al.,
2012; Mozaffarian et al., 2015; Pedersen et al., 2015)]. One
popular form of WL diet is intermittent fasting (IF), which
utilizes repeated short-term fasts to reduce energy intake,
promote WL, and improve the lipid profile (Tinsley and La
Bounty, 2015). IF has been shown to be as effective as continuous
energy restriction in terms of WL, reducing TG, low-density
lipoprotein (LDL) cholesterol, and blood pressure (BP; Harvie
et al., 2011; Varady, 2011). However, the impact of IF on
vascular compliance, an indicator of cardiovascular disease risk
(Vlachopoulos et al., 2010), has not been examined. There is
also limited information concerning whether men and women
differ in their responses to short-term IF. Additionally, IF diets
have not been examined in combination with high protein intake
aimed at promoting cardiovascular health. Thus, the first aim
of this study is to examine if there are sex differences in terms
of lipid profile, and arterial compliance following a short-term
high-protein, intermittent fasting, low-calorie (HP-IF-LC) diet.
WL induced by nutritional interventions, such as a HP-IF and
a traditional heart healthy (HH) diet, has demonstrated beneficial
effects on minimizing cardiovascular risk factors (Arciero et al.,
2006; Camhi et al., 2010; Song et al., 2016). HH diets exert a
protective effect on the heart, as evidenced by reduced rates of
myocardial infarction (Hansen-Krone et al., 2012). On the other
hand, HP diets contribute to WL and weight loss maintenance
(WL-M) by increasing the metabolic rate (Leidy et al., 2015). HP
diets also induce extra energy expenditure via protein and urea
synthesis as well as gluconeogenesis (Westerterp-Plantenga et al.,
2009). Although multiple studies have demonstrated the short-
term benefits of HP and IF diets, there is little research focusing
on the combined or long-term effects of HP-IF diet on blood
lipids, arterial compliance and CVD risk reduction in adults
with obesity during and after a short-term WL intervention
(Mattson and Wan, 2005; Varady, 2011). Clinical trials have
demonstrated the independent effects of either HP, IF, or LC
diets on improving cardiovascular outcomes in individuals with
obesity (Katare et al., 2009; Harvie et al., 2011; Damsgaard et al.,
2013; de Luis et al., 2016). However, few studies emphasize the
combined effects of each of these dietary strategies on long-
term WL-M and cardiovascular health. Higher protein intake
during IF with low energy intake may be beneficial for WL and
WL-M due to improved preservation of fat-free mass and resting
metabolic rate. Therefore, the second major aim of the current
study was to compare the effects of two differentWL-M strategies
(HP-IF vs. HH) on blood lipids, and arterial compliance in adults
with obesity following an initial short-term HP-IF-LCWL diet.
MATERIALS AND METHODS
Participants
Eligible volunteers were randomly recruited from the Saratoga
Springs, NY area. Participants were eligible for inclusion in the
study if they were healthy non-smokers, but were overweight or
obese. A comprehensivemedical examination/history assessment
was performed by their physicians. Individuals were excluded
from participation in the study if they had any previous
cardiovascular or metabolic disease, or were receiving hormone
therapy which could influence weight status, central adiposity
and CVD risk factors measured in this study. Additionally,
only individuals who were either sedentary or lightly active
(<30min, 2 days/week of organized physical activity), weight
stable (± 2 kg during the past 6 months), middle-aged, and non-
alcoholic, based on self-report, were eligible for inclusion in the
study. Every participant provided written informed consent in
accordance with the Skidmore College Human Subjects Review
Board prior to participation, and the study was approved by
the Human Subjects Institutional Review Board of Skidmore
College (IRB #: 1307-347). All experimental procedures were
performed in adherence with New York State regulations and
the Federal Wide Assurance, which are consistent with the
National Commission for the Protection of Human Subjects of
Biomedical and Behavioral Research, and in agreement with the
Helsinki Declaration (revised in 1983). This trial was registered
at clinicaltrials.gov as NCT02525419.
Experimental Design and Study Timeline
Forty subjects with obesity were enrolled as a single cohort
in this 64-week dietary regimen, splitting into two consecutive
intervention phases: (a) 12-week WL (Phase 1) with HP-IF-LC
diet (1-week baseline control, 10-week WL, 1-week post-testing)
comparing men and women, and (b) a 1-year WL-M (Phase
2) comparing two diets (HP-IF vs. HH). All laboratory testing
procedures were completed following baseline control (week 0),
WL (week 12), and WL-M (week 64), as shown in Figure 1.
During baseline control, the height, and body weight were
recorded for each participant. In order to maintain stable weight,
subjects were asked to maintain routine eating patterns and
record dietary food logs for 2 days during baseline control period.
In order to verify sedentary/low activity levels, all participants
wore an Actical accelerometer (Bio-Lynx Scientific Equipment
Inc., Montreal Quebec, Canada) around their waist for 2 days
during weeks 0, 5, and 10. At weeks 0, 12, and 64, body weight
was assessed between 6:00 and 9:00 a.m., after an overnight
fast. Subjects then rested in a supine position for 15-min in
a quiet and dimly lit room before a fasted blood draw was
performed for assessment of blood lipids and measures of arterial
compliance were obtained (see Laboratory Testing Procedures).
Following control baseline testing, participants were provided
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FIGURE 1 | Schematic illustrating the experiment timeline comprised of a 12-week WL (phase 1), followed by a 52-week WL-M (phase 2). HP-IF-LC,
high-protein, intermittent fasting, low-calorie; HH diet, heart healthy diet; WL, weight loss; WL-M, weight loss maintenance.
with detailed instructions on their WL dietary guidelines (see
Dietary Intervention) and scheduled their weeklymeeting with a
licensed registered dietitian. At the beginning ofWL-M (Phase 2),
all subjects continued to meet with a dietitian, but on a monthly
basis.
Rationale
A HH diet that meets the guidelines of the American
Heart Association is comprised of 50–60% of energy from
carbohydrates and approximately 15% from protein, with
the remaining 25–35% from healthy fats. This diet is often
recommended to improve cardiovascular health independent of
WL (Fagerberg et al., 1984; Trumbo et al., 2002; Lichtenstein
et al., 2006). Thus, it is of great interest to systematically compare
the relative effectiveness of this HH diet and other diets, such as
a HP-IF diet, in individuals with obesity during WL and long-
termWL-M. In this context, using a two-phase study design, our
first objective was to determine whether men and women with
obesity demonstrate similar cardiovascular health improvements
following a 12-week HP-IF-LC diet. Thereafter, we aimed to
quantitatively compare the effectiveness of 52 weeks of a HP-
IF vs. HH diet on WL-M and maintenance of cardiovascular
enhancements produced by WL.
Dietary Intervention
WL (Phase 1, Weeks 1–12): HP-IF-LC Diet
Beginning at week 1, subjects consumed a HP-LC diet 6 days per
week, along with an IF diet on the remaining day of the week.
This diet was adhered to in conjunction with weekly counseling
sessions with a registered dietitian. The composition of the HP-
LC diet and the timing of meals are shown in Table 1. In order
to induce an energy deficit without compromising lean body
mass, the daily macronutrient distribution (30% protein, 45%
carbohydrate, and 25% fat) has been used in this phase based
on our previous study (Arciero et al., 2014). Total energy intake
during HP-LC was 1200 and 1500 kcal per day for females
and males, respectively. The eating schedule was designed to
produce a regular frequency of meals and protein consumption
during the WL and WL-M interventions. During WL, each
meal consisted of approximately 20–30 g servings of high-quality
protein in either whole food or supplement form. Subjects were
told to eat 4–5 meals per day on HP-LC days, as depicted
in Table 1. On the one IF day per week, daily energy intake
consisted of 330 and 430 kcal for women and men, respectively.
The composition of the diet for the IF day is depicted in
Table 2.
WL-M (Phase 2, Weeks 13–64): HP-IF and HH Diets
Starting at week 13, participants chose whether to enter the HP-
IF or HH diet group for Phase 2 of the study. Both groups
(n = 10 for HP-IF; n = 14 for HH) received monthly dietary
counseling from a registered dietitian, and subjects in both
groups reported continued desire to lose weight after the initial 12
weeks. In order to resemble free-living conditions (i.e., conditions
without excessive supervision), subjects were instructed to follow
the guidelines of their respective diets without restrictions
on physical activity or total food intake. However, they were
encouraged to stay at an intake level necessary for weight
maintenance, based on their calculated energy needs [measured
resting metabolic rate (RMR) X Activity Factor]. The HP-IF
group were provided 2 meal replacements per day (either two
protein powder packets or one protein powder packet and one
meal replacement bar) while the remaining 2–3meals were whole
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TABLE 1 | Composition of high-protein low-calorie diet.
Meal and recommended
time of consumption
Energy (kcal)a Description
Breakfast (6:00–8:00 A.M.) 240 Liquid meal replacementb
Lunch (11:00 A.M.–1 P.M.) 240 Liquid meal replacementb
Afternoon snackc
(2:00–4:00 P.M.)
150 Low-glycemic protein wafers or
whole-food high protein snackfg
Dinnerd (5:00–7:00 P.M.) 450 or 600
Evening snack (9:00–10:00
P.M.)
270 Meal replacement bare
aThe total daily macronutrient distribution for the HP-LC diet shown above was 30%
protein, 45% carbohydrate, and 25% fat, and total energy intake for males and females
was ∼1500 and 1200 kcal, respectively. In addition to following this HP-LC diet 6 days
per week, an IF diet was followed for one day per week.
b Isalean Shake, Isagenix LLC, Chandler, AZ, USA.
cAfternoon snack was consumed by males only.
dFemales consumed 450 kcal meal while males consumed 600 kcal meal.
e Isalean Bar, Isagenix LLC, Chandler, AZ, USA.
fSnack components for men: 2 hard-boiled egg with 1/3 cup fruit; 6 oz. cottage cheese
with 1/3 cup fruit; 1 tbsp of nuts and 1/3 cup of fresh veggies or fruit; 1 slice of whole
grain bread with 1.5 tsp nut butter; 1/2 cup Fresh fruit or veggies with 1/3 cup hummus;
8 oz plain greek yogurt; ¼ cup granola.
gSnack components for women:1 hard-boiled egg with ¼ cup fruit; 4 oz. cottage cheese;
¼ cup fruit; 4 oz. plain non-fat greek yogurt;¼cup granola;½ slice bread;¾ tsp nut butter;
¼ cup fruit or veggies with 1/5 tbsp hummus.
TABLE 2 | Composition of intermittent fasting diet.
Food item/dietary
supplement
Consumption
frequency
Descriptiona
Whole-food high protein
snack
1/day 100 or 200 kcal for females and
males, respectively
Anti-oxidant rich powderb 6/day 120 kcal total
Low-glycemic protein
wafersb
3/day 90 kcal total
Micronutrient supplementc 2/day Contains vitamins, minerals,
phytonutrients, antioxidants, and
essential fatty acids
Herbal supplementd 1/day Multiple ingredients, such as
wolfberry, kiwi, rhodiola root, harada,
tribulus, and maca root
aDuring the Phase 1 (weight loss) of the study, participants performed one day of IF per
week, which consisted of a total energy intake of 330 kcal/d for women and 430 kcal/d
for men.
b Isalean Shake, Isagenix LLC, Chandler, AZ, USA.
cAgeless Essentials with Product B, AM & PM, Isagenix LLC, Chandler, AZ, USA;
consumed on IF and non-IF days.
d Ionix Supreme, Isagenix LLC, Chandler, AZ, USA; consumed on IF and non-IF days.
foods, as guided by a dietitian. HP-IF subjects also performed IF
1 to 2 days per month.
The HH group followed the dietary guidelines that are in
compliance with the National Cholesterol Education Program
Therapeutic Lifestyle Changes diet (i.e., <35% of kcal as fat; 50–
60% of kcal as carbohydrates;<200 mg/dL of dietary cholesterol;
and 20–30 g/day of fiber). Both groups (HH and HP-IF) had
monthly meetings with a registered dietitian to establish healthy
eating choices that were compliant with their meal plans.
Additional counseling with the registered dietitian was made
available to participants if necessary. During WL-M, the same
timing of meals as during WL was implemented (i.e., 4–5 meals
per day evenly spaced throughout the day). The only exception
was during IF days for the HP-IF subjects.
Compliance
To encourage compliance, all subjects had weekly meetings
with a registered dietitian during WL and monthly meetings
during WL-M to incorporate healthy eating strategies while
consuming their appropriate diet. Additionally, all subjects were
given detailed written and verbal instructions for each diet
plan (HP-IF-LC; HP-IF; HH). For example, participants were
informed that HP-IF was designed to maintain intake close
to the 1.8 g protein/kg body weight (BW), whereas the HH
was designed to deliver 1.0 g protein/kg BW. Furthermore, as
stated above, there were no differences between the subjects
choosing HH or HP-IF diets for the WL-M phase. Monitoring of
the meal plans was performed through daily subject-researcher
interaction (e.g., telephone conversations, 2-day food diary
analysis, weekly dietary intake journals inspections, distribution
of weekly meal/supplement containers, return of empty packets
and containers, and monthly group meetings). The PI (PJA)
and/or an investigator held weekly meetings with all participants
to verify compliance with the dietary meal plans, clarify dietary
guidelines, and answer questions. Participants demonstrated a
high compliance rate (>90%), which was defined as consuming
more than 85% of their respective meals/supplemented feedings.
Subjects were considered non-compliant if they were absent
from more than two consecutive dietitian meetings or consumed
≥3 inappropriate meal/supplement servings a week for ≥2
consecutive weeks at a time.
A 2-day food record was utilized to verify compliance to
each respective diet (HP-IF-LC; HP-IF; HH). Based on our
experience, a representative sample of only 2 days was adequate
to assess subjects’ stable and consistent intake during each stage.
If necessary, subjects were instructed to record food intake every
day. Food records were filled out by the participants at weeks 0,
11, and 63. A registered dietitian and a research team member
provided instructions to the participants on making detailed
records of portion sizes and food items. The dietary information
was subsequently recorded into the food analysis program, The
Food Processor SQL Edition (version 10.2.0 ESHA Research,
Sale, OR, 2012). Single trained operators (E.W.) performed the
analysis in order to eliminate inter-investigator variation. Each
participant was also given a checklist in an effort to help adhere
to the IF day regimen.
Laboratory Testing Procedures
BW and Physical Activities Assessment
Body weight was measured using an electronic scale during each
testing visit without shoes and in minimal clothing. Standard
BMI measurements were obtained by dividing the participant’s
weight (kg) by the square of their height (m2). Free-living, daily
activity was monitored by an Actical accelerometer secured on
the waist to ensure consistent levels of activity between the
participants (Esliger et al., 2007; Hooker et al., 2011).
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Blood Lipid Determination
A 12-h fasted venous blood sample (∼20 ml) was obtained at
baseline (week 0) and post-intervention (weeks 12 and 64). Blood
was collected into EDTA-coated vacutainer tubes and centrifuged
(Hettich Rotina 46R5) for 15 min at 2500 rpm at 4◦C. After
separation, plasma was stored at −70◦C in small aliquots until
analyzed. TC, high-density lipoprotein (HDL) cholesterol, and
TG were assessed using the Cholestech LDX blood analysis
system (Hayward, CA). Test-retest intraclass correlation (r) and
coefficient of variation (CV) with n = 15 is: r = 0.95, CV =
3.2%, and r = 0.97, CV = 5.3%, for TC and HDL cholesterol,
respectively.
Vascular Compliance Measurement
Vascular compliance can be measured non-invasively and gives
information regarding cardiovascular disease risk, even in
healthy individuals (Ring et al., 2014). Resting heart rate (HR)
and systolic and diastolic BP (SBP; DBP) were obtained in the
supine position as previously described (4, 6, 7). HR and BP were
obtained by the same investigator (E.W.) following a minimum
of 10 min of quiet resting.
The Arteriograph (version 1.10.0.1, TensioMed Kft.,
Budapest, Hungary) device uses an upper arm cuff inflated
to >35 mmHg above the subjects’ actual systolic pressure. This
causes a small diaphragm in the brachial artery to develop along
the upper border of the over-pressurized cuff. A pulse wave
is created as the central pressure changes, forming an early
(direct) systolic wave (P1), late (reflected) systolic wave (P2), and
diastolic wave(s) (P3). The device is able to record each of these
suprasystolic pressure changes.
Initially, the Arteriograph measures the systolic and diastolic
BP oscillometrically, and then decompresses the cuff. Within a
few seconds, the device re-inflates the cuff, first to the actual
measured diastolic BP followed by the suprasystolic pressure,
which is 35 mmHg over the actual systolic BP. The device records
the signals from both pressure levels for 8 s. A computer receives
all of the signals sent wirelessly by the device. Using the software,
the augmentation index is determined by the following formula:
Aix (%) = (P2 − P1)/PP× 100
where P1 reflects the early direct wave’s amplitude; P2 refers
to the late reflected systolic wave’s amplitude; and PP equals
the pulse pressure. Augmentation index was calculated for the
brachial artery (brachial augmentation index; BAIX) and for
the aorta (central augmentation index; CAIX). CAIX values
are produced by the Arteriograph based on the correlation
between previous simultaneously measured brachial and aortic
augmentation indices. The aortic pulse wave velocity (PWVao)
is determined by the wave reflection generated from the early
direct pulse wave as it is reflected back primarily from the
aortic bifurcation. Return time (RT) is determined by measuring
the time interval between peaks from the early direct (P1) and
reflected late (P2) systolic waves. The PWVao calculations were
measured using the distance from the upper edge of the pubic
bone to the sternal notch (Jugulum-Symphisis¼), as this provides
the closest approximation of the true aortic length (Sugawara
et al., 2008; Horváth et al., 2010). The parallel straight-line
distance between these anatomical points was measured to allow
for the calculation of the PWVao with the following formula:
PWVao(m/s) = [Jug− Sy(m)]/[(RT/2(s)]
Finally, calculation of the blood pressure using the Arteriograph
was based on algorithms that have been previously validated
(Németh et al., 2002; Horváth et al., 2010).
Statistical Analysis
Statistical analysis was performed using SPSS software (Ver.
21; IBM-SPSS). All values are reported as means ± SE. Before
the start of the study, sample size was determined through
power analysis based on the major outcome variables (blood
lipids and arterial compliance) to achieve an effect size of 0.25
with 80% power at alpha 0.05 based on the preliminary data.
This analysis determined that n = 12 were required to detect
significant differences between groups. A 2 × 2 factor repeated
measures ANOVA (RMANOVA) was performed for the WL
(HP-IF-LC, weeks 0–12) phase (sex; M/F and time; control
baseline vs. 12 Weeks) and the WL-M (weeks 13–64) phase
(group; HP-IF/HH and time; 13 weeks vs. 64 weeks) to determine
main effects as shown in the results. Bonferroni’s method
was performed if there was an interaction between variables.
A multivariate ANOVA was also performed as an additional
analysis. Pearson’s correlation coefficients were used to assess
the relationships between body fat, blood lipids, cardiovascular
function, and arterial compliance during WL and WL-M phases.
The significance was set at p < 0.05, and trends were noted
for 0.05 < p < 0.1. Percent change for dependent variables was
calculated as
(measurement 2) − (measurement 1)
measurement 1 ∗ 100.
RESULTS
WL (Phase 1, HP-IF-LC Diet)
Forty participants completed Phase 1 of this study. Descriptive
baseline characteristics of the participants are shown in
Table 3. Results of the repeated-measures ANOVAs for our
TABLE 3 | Baseline (week 0) characteristics of participants for WL
(Phase 1).
Male (n = 21) Female (n = 19) Total (n = 40)
Characteristics Mean SE Mean SE p-value Mean SE
Age (years) 46.1 1.5 50.0 2.3 0.163 48.0 1.4
Weight (kg) 120.1 4.8 99.5 2.8 0.001 110.3 3.3
Height (cm) 179.0 1.7 163.1 1.0 0.000 171.4 1.6
BMI (kg/m2) 37.5 1.5 37.4 1.1 0.945 37.5 0.95
HR (bpm) 65.0 1.9 64.7 2.8 0.430 64.9 1.6
SBP (mmHg) 127.7 2.1 121.9 2.7 0.034 125.2 1.7
DBP (mmHg) 81.7 2.4 76.9 2.6 0.098 79.5 1.8
BMI, body mass index; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood
pressure.
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TABLE 4 | Results of weight loss phase (Phase 1).
Gender Baseline 12 weeks p-value (interaction) p-value (time) p-value (gender)
BMI (kg/m2) M 38.3±1.6 34.3±1.3 0.715 < 0.001* 0.598
F 37.4±1.1 33.7±1.0
TC (mg/dL) M 188.2±7.9 160.8±6.6 0.670 < 0.001* 0.219
F 199.6±9.6 168.7±8.2
LDL (mg/dL) M 114.6±6.7 104.1±6.4 0.505 0.036* 0.644
F 121.0±6.9 104.0±5.8
HDL (mg/dL) M 48.2±3.1 43.5±2.8 0.846 0.006* 0.550
F 51.1±3.1 45.7±2.7
TG (mg/dL) M 134.2±17.7 84.9±10.7 0.686 < 0.001* 0.307
F 144.3±13.7 102.7±9.1
HR (bpm) M 65.5±2.2 60.8±2.3 0.878 0.017* 0.867
F 64.8±2.8 60.6±2.3
SBP (mmHg) M 126.3±2.0 116.5±2.5 0.426 0.002* 0.195
F 121.9±2.7 115.3±2.0
DBP (mmHg) M 80.1±1.8 72.6±1.8 0.783 < 0.001 0.158
F 76.9±2.6 68.7±1.8
PWVao (m/s) M 7.8±0.4 7.2±0.3 0.571 0.001* 0.764
F 7.8±0.3 6.9±0.3
BAIX (%) M −27.0±6.5 −37.3±4.4 0.289 0.134 0.035**
F −10.6±7.4 −12.6±7.3
CAIX (%) M 24.0±3.3 18.8±2.2 0.289 0.133 0.035**
F 32.3±3.7 31.2±3.7
Return Time (s) M 142.4±6.0 157.4±4.9 0.752 < 0.001* 0.101
F 128.3±5.4 146.1±5.1
Data presented as mean ± SE. Return time refers to the time intervals between peaks from the early direct and reflected late systolic waves. *Significant difference based on time (p <
0.05); **Significant difference between genders (p < 0.05). BMI, body mass index; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TG, triglycerides;
HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; PWVao, pulse wave velocity; BAIX, brachial augmentation index; CAIX, central augmentation index; M, male;
F, female.
dependent variables are displayed in Table 4. No gender-by-
time interactions were found for any variables after Phase 1.
The average loss of BW reached 10% of original BW following
the 12-week WL (10.4 ± 0.6%, p < 0.001). BMI was also
significantly decreased post Phase 1 compared to baseline (BMI:
37.5 ± 0.9 vs. 33.7 ± 0.8 kg/m2, p < 0.001; Figures 2A,
4A). However, there was no difference observed in BMI at
week 12 between those who chose to enter either the HH or
HP-IF groups.
Significant decreases were also found in the levels of plasma
TG, LDL, and TC following the WL (Figures 3A–D). As
expected, HR and BP were also significantly decreased following
the 12 weeks WL (Figures 4B–D); however, HR only decreased
in male subjects.
Moreover, our results revealed that PWVao, an important
measurement of arterial stiffness, was significantly decreased
whereas the return time (RT) was increased following Phase 1
(Figures 4E,F). There were not significant changes in BAIX or
CAIX (Figures 4G,H).
Percent changes in anthropometrics (BW and BMI) were
significantly positively correlated with the corresponding
changes in plasma TG (r = 0.30, 0.30, p < 0.05, respectively)
and TC (r = 0.45, 0.48, p < 0.01, respectively), but not with the
ratio of TC/HDL (Table 5). Interestingly, the percent change
FIGURE 2 | Dietary effects on BMI during phase 1 (A) and phase 2 (B)
collapsed across genders. (A) Effect of 12 week HP-IF-LC intervention
(Phase 1) on BMI (n = 40). (B) Percent change in BMI between HP-IF and HH
groups during Phase 2 (n = 24). ***Significant difference compared to baseline
(p < 0.001). *Trend for significant difference compared to HH group (p =
0.069). BMI, body mass index; HP-IF, high-protein, intermittent fasting; HH,
heart healthy.
in CAIX was significantly correlated with HR, systolic BP,
and diastolic BP (r = −0.29, r = −0.31, r = 0.29, p < 0.05,
respectively).
WL-M (Phase 2, HP-IF, and HH Diets)
Male and female participants were pooled for Phase 2. Twenty-
four participants successfully completed Phase 2, while 16 were
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FIGURE 3 | Effect of 12 week HP-IF-LC intervention (Phase 1) on (A)
triglycerides, (B) LDL, (C) total cholesterol, (D) total cholesterol/HDL
ratio of males and females. Significant difference compared to baseline of
the same gender indicated by: *p < 0.05; **p < 0.01; ***p < 0.001. LDL,
low-density-lipoprotein; HDL, high-density-lipoprotein.
excluded due to drop-out and non-compliance. Descriptive
characteristics of the participants are shown in Table 6, and the
results of the repeated measures ANOVAs for our dependent
variables are displayed in Table 7. TC, LDL, HDL, TG, HR,
SBP, DBP, and return time increased over time in both groups.
However, there were trends (0.05 < p < 0.1) for less regain
in BMI (p = 0.069; Figure 2B) and LDL (p = 0.068) in the
HP-IF group. There was also a reduced PWVao in the HP-IF
group (p = 0.045) and increased CAIX over time in both groups
(p= 0.084).
No significant difference was observed at the beginning of
Phase 2 between the HP-IF and HH groups for any blood
lipid components. Although there were no statistically significant
differences in respect to the changes in blood lipid profiles
between the HP-IF and HH groups following Phase 2, the HP-
IF group demonstrated a tendency toward lower percentage
increases compared to HH group in all lipid profiles except HDL
(Figures 5A–F).
Our results did not show a meaningful difference between
the HP-IF and HH groups in terms of systolic BP, diastolic BP,
or HR following phase 2. It is worth noting that the percent
change in PWVao was much less in the HP-IF group than in
the HH group following Phase 2 (−2.5 ± 4.1% vs. 11.2 ± 4.6%;
Figure 6A). The difference in return time following the WL-M
phase was also noticeable (HP-IF: −4.6 ± 3.8% vs. HH: −11.8
± 3.0%, p = 0.220), although it was not statistically significant
(Figure 6B). BAIX and CAIX percent changes are depicted in
Figures 6C,D.
The percent change in systolic and diastolic BP was positively
correlated with changes in BAIX (r = 0.52, p < 0.05; r =
0.63, p < 0.01, respectively). We also found that changes in
TRG were positively correlated with changes in LDL, BAIX, and
CAIX (r = 0.42, r = 0.49, r = 0.50, p < 0.05, respectively;
Table 8).
DISCUSSION
Previous studies have supported the independent effects of
HP, HH, LC, or IF diets on WL success and cardiometabolic
improvement (Arciero et al., 2006; Kelishadi et al., 2008;
Clifton et al., 2009; Camhi et al., 2010; Klempel et al., 2012;
Song et al., 2016). The current study provides convincing
evidence that the combined HP-IF-LC diet successfully induces
marked body WL, and is likely associated with reduced blood
lipid levels and enhanced arterial compliance among men
and women with obesity. During WL (Phase 1), the percent
change in BW and BMI was significantly correlated with the
changes in certain blood lipid variables such as TRG and TC.
Subsequently in WL-M (Phase 2), subjects who adhered to the
HP-IF diet experienced reduced weight regain and demonstrated
better arterial compliance than those consuming the HH diet.
Collectively, these data suggest that the HP-IF diet may be a new
type of healthy diet which could be advantageous in maintaining
the long-term health benefits from initial WL in overweight and
obese individuals. Although significantWL occurred in bothmen
and women, we found no sex effect in the parameters of our
study.
The alarming rate of obesity in the United States is often
attributed to the consumption of low-quality, high caloric diets
(Bruemmer, 2012). Obesity was established as an independent
risk contributor for CVD in the 26 plus-year follow-up from
the original Framingham cohort study (Hubert et al., 1983).
Numerous studies have investigated WL and the corresponding
alterations in cardiovascular health and disease risk (Kelishadi
et al., 2008; Clifton et al., 2009; Klempel et al., 2012; Mozaffarian
et al., 2015; Pedersen et al., 2015). However, a major challenge
we currently face is effectively maintaining successful WL and
the accompanying health benefits. Therefore, it is paramount that
researchers and clinicians developWL strategies that are also safe
and effective for aiding in long-term heart health (Bruemmer,
2012). While recidivism often appears to be unavoidable in
long-term WL studies, maintaining even modest WL can be
clinically significant (Stevens et al., 2001; Harsha and Bray,
2008).
Research has reported that short-term interventions similar
to our HP-IF-LC diet effectively promote WL (Clifton et al.,
2009; Klempel et al., 2012). One novel aspect of our study was
comparing a traditional HH diet with a HP-IF diet using a 1-
year follow-up to the initial 12-week WL period. We tracked
changes in BMI, blood lipids, as well as cardiovascular and
arterial compliancemeasures during bothWL andWL-Mphases.
This could be attributed to the relatively higher protein content
in the HP-IF diet, but the 1 to 2 days per month of IF likely
exerted beneficial effects by counteracting normal weight gain.
The individual and combined effects of HP and IF warrant
further investigation.
The combined diet plan (HP-IF-LC) utilized in this study
is not overly complex, and the modified IF that was included
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FIGURE 4 | Effect of 12 week HP-IF-LC intervention (Phase 1) on (A) BMI, (B) heart rate, (C) systolic blood pressure, (D) diastolic blood pressure, (E)
PWVao, (F) return time (the time intervals between peaks from the early direct and reflected late systolic waves), (G) BAIX, and (H) CAIX of males and
females. Significant difference compared to baseline of the same gender indicated by: *p < 0.05; **p < 0.01; ***p < 0.001. BMI, body mass index; PWVao, aortic
pulse wave velocity; BAIX, brachial augmentation index; CAIX, central augmentation index.
TABLE 5 | Pearson correlation coefficients for the percent change in body weight/BMI and blood lipid profiles following the phase 1 study.
TRG (% 1) LDL (% 1) TC (% 1) TC/HDL (% 1)
Body metrics r-value p-value r-value p-value r-value p-value r-value p-value
Body weight (% 1) 0.30 0.03* 0.22 0.09 0.45 0.00** 0.22 0.09
BMI (% 1) 0.30 0.03* 0.27 0.05 0.48 0.00** 0.19 0.12
BMI, body mass index; TRG, triglycerides; LDL, low density lipoprotein; TC, total cholesterol; TC/HDL, total cholesterol/high density lipoprotein ratio. *Significantly correlated (p < 0.05).
**Significantly correlated (p < 0.01).
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during the WL-M phase was only employed on 1 to 2 days per
month. The HP-IF diet provided sufficient energy intake and
was not intended for continued weight loss during the WL-M
phase. Rather, it was included simply to more closely mimic the
diet during the WL phase without the intended WL. Moreover,
both HP and IF have been reported to induce significant health
TABLE 6 | Baseline (week 12) characteristics of participants for WL-M
(Phase 2).
HP-IF (n = 10) HH (n = 14) Total (n = 24)
Characteristics Mean SE Mean SE p-value Mean SE
Age (years) 50.9 3.1 50.0 1.8 0.791 50.4 1.6
Weight (kg) 90.4 2.4 95.1 3.7 0.306 93.1 2.4
Height (cm) 169.6 3.1 170.2 3.3 0.903 169.9 2.3
BMI (kg/m2) 31.6 0.82 33.1 1.3 0.076 32.5 0.81
HR (bpm) 57.4 2.8 58.7 2.7 0.607 58.2 1.9
SBP (mmHg) 114.0 3.3 110.9 2.5 0.534 112.2 2.0
DBP (mmHg) 68.9 2.6 69.3 2.0 0.859 69.1 1.5
BMI, body mass index; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood
pressure.
benefits, thus this was a logical dietary intervention to compare
to the HH diet.
Previous research has shown that elevated resting HR can
predict cardiovascular mortality in men and women (Fox et al.,
2007; Cooney et al., 2010). Hypertension, which is associated with
obesity, is also known to predispose individuals to CVD (Aucott
et al., 2005). These serve as additional support for the necessity of
long-termWL interventions which can sustain improvements in
these significant cardiovascular variables. In addition, it is well-
known that WL in hypertensive individuals is associated with
a decrease in BP in short-term interventions either by caloric
restriction, exercise, or both (Neter et al., 2003; Elmer et al., 2006;
Harsha and Bray, 2008). Nevertheless, long-term studies on the
effects of WL induced by different diets on BP are still lacking.
As such, we measured systolic and diastolic BP, as well as resting
heart rate, at weeks 0, 12, and 64. We observed a decline in
systolic BP and diastolic BP following the 12-week WL Phase.
However, the participants in the present study were, on average,
categorized as having normal BP at study commencement, so
the complete impact of these BP reductions is not entirely clear,
although they could potentially aid in preventing a rise in BP over
time. Some degree of weight relapse occurred during the WL-
M phase, although body weight and BMI still remained below
TABLE 7 | Results of weight loss maintenance phase (Phase 2).
Diet Baseline (week 12) 64 weeks p-value (interaction) p-value (time) p-value (diet)
BMI (kg/m2) HP-IF 31.6 ± 0.8 31.8 ± 1.2 0.069* 0.102 0.264
HH 32.2 ± 1.4 34.0 ± 1.4
TC (mg/dL) HP-IF 157.6 ± 8.4 184.4 ± 11.9 0.339 <0.001** 0.664
HH 158.0 ± 12.8 195.2 ± 11.1
LDL (mg/dL) HP-IF 101.5 ± 7.7 113.1 ± 8.6 0.068* 0.002** 0.715
HH 90.0 ± 8.5 116.8 ± 11.3
HDL (mg/dL) HP-IF 38.4 ± 3.2 50.1 ± 3.1 0.107 0.001** 0.365
HH 46.8 ± 4.7 51.6 ± 4.5
TG (mg/dL) HP-IF 96.1 ± 12.0 124.1 ± 21.3 0.281 0.007** 0.764
HH 91.0 ± 15.5 142.4 ± 22.9
HR (bpm) HP-IF 57.4 ± 2.8 60.0 ± 2.9 0.367 0.008** 0.677
HH 57.5 ± 2.7 62.5 ± 1.7
SBP (mmHg) HP-IF 114.0 ± 3.3 130.8 ± 4.4 0.706 0.001** 1.000
HH 112.8 ± 2.9 132.0 ± 5.3
DBP (mmgHg) HP-IF 68.9 ± 2.6 80.7 ± 2.9 0.987 <0.001** 0.514
HH 70.8 ± 2.2 82.5 ± 3.8
PWVao (m/s) HP-IF 7.4 ± 0.6 7.0 ± 0.3 0.094* 0.665 0.992
HH 6.9 ± 0.3 7.5 ± 0.4
BAIX (%) HP-IF −9.2 ± 14.1 −10.2 ± 14.5 0.156 0.025 0.641
HH −36.8 ± 7.4 −15.9 ± 6.7
CAIX (%) HP-IF 30.9 ± 6.0 31.6 ± 5.8 0.288 0.084* 0.812
HH 26.3 ± 3.7 32.7 ± 4.0
Return Time (s) HP-IF 146.6 ± 8.2 138.3 ± 6.8 0.220 0.002** 0.797
HH 156.0 ± 7.4 134.7 ± 7.2
Data presented as mean ± SE. Return time refers to the time intervals between peaks from the early direct and reflected late systolic waves. *Trend for significant difference (0.05 < p
< 0.1); **Significant difference based on time (p < 0.05). BMI, body mass index; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TG, triglycerides; HR,
heart rate; SBP, systolic blood pressure; PWVao, pulse wave velocity; BAIX, brachial augmentation index; CAIX, central augmentation index; HP-IF, high-protein intermittent fasting; HH,
heart healthy.
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FIGURE 5 | Percent changes in (A) triglycerides, (B) LDL, (C) HDL, (D) non HDL lipids, (E) total cholesterol, and (F) total cholesterol/HDL ratio between
the HP-IF and HH groups following Phase 2 (52 weeks). HP-IF, high-protein, intermittent fasting; HH, heart healthy; LDL, low-density lipoprotein; HDL,
high-density-lipoprotein.
FIGURE 6 | Percent changes in (A) PWVao, (B) return time (the time
intervals between peaks from the early direct and reflected late
systolic waves), (C) BAIX, and (D) CAIX between the HP-IF and HH
groups following Phase 2 (52 weeks). *Significant difference from the HH
group (p = 0.045), as assessed by repeated-measures ANOVA. PWVao, aortic
pulse wave velocity; HP-IF, high-protein, intermittent fasting; HH, heart healthy;
BAIX, brachial augmentation index; CAIX, central augmentation index.
baseline levels. During the weight relapse, simultaneous increases
in HR and BP were seen, but neither diet (HP-IF or HH) was
shown to be more advantageous in lessening the recidivism in
either BP or HR during the WL-M phase. In the future, extensive
studies requiring a larger sample and longer-term interventions,
possibly combined with exercise regimens, are needed to evaluate
the advantages of the health-promoting effects of HP-IF on BP
and HR changes.
The degree of WL has previously been linked to the reduction
of CVD risk factors (Van Gaal et al., 2005). Consistent with
previous studies (Melanson et al., 2003; Harder et al., 2004), we
found that a 12-weekWL programmarkedly reduced triglyceride
levels and moderately lowered LDL (−25 and −11% in the
present study), without improvements in HDL. In the future,
moderate exercise combined with the HP-IF dietary intervention
might be a promising approach to increase HDL levels while
still reducing triglycerides and LDL. Following the 1 year WL-M
phase, the improved lipid risk factors rebounded slightly, which
was associated with recidivism of the weight gain. Although the
weight relapse seems to be common for long-term WL studies,
Wing et al. concluded that large or modest WL at 1 year is still
clinically beneficial for diabetic patients with obesity (Wing et al.,
2011), and it has been reported that acute weight loss affects long-
term cardiovascular function (Corbi et al., 2002). Further studies
should address the additional factors associated with CVD risk,
such as the presence of diabetes and race difference, as well as the
use of Framingham risk score to understand the beneficial effects
of HP-IF diet.
An augmentation index is used as a measure of arterial
stiffness, which has been demonstrated to adversely affect
cardiovascular health (Nürnberger et al., 2002). For example,
type 1 and type 2 diabetes are both characterized by increased
arterial stiffness (Wilkinson et al., 2000). Our data revealed
non-significant reductions in BAIX and CAIX after Phase 1, as
well as a reduction in PWVao in the HP-IF group compared
to the HH group in Phase 2. This finding suggests that the
participants in the HP-IF group may have benefits from reduced
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TABLE 8 | Pearson correlation coefficients for the percent change in variables following the phase 2 study.
LDL (% 1) BAIX (% 1) CAIX (% 1) PWVao (% 1)
r-value p-value r-value p-value r-value p-value r-value p-value
Systolic BP (% 1) −0.22 0.17 0.52 0.01* 0.05 0.41 0.11 0.32
Diastolic BP (% 1) −0.19 0.20 0.63 0.00** 0.30 0.10 −0.28 0.12
TRG (% 1) 0.42 0.03* 0.49 0.02* 0.50 0.01* −0.27 0.12
LDL, low density lipoprotein; BAIX, brachial augmentation index; CAIX, central augmentation index; PWVao, aortic pulse wave velocity; TRG, triglycerides; BP, blood pressure. *Significantly
correlated (p < 0.05). **Significantly correlated (p < 0.01).
arterial stiffness as a result of continuing the HP-IF diet for 1
year. Our data also suggest a positive relationship between the
changes of BAIX, CAIX, and the change in TRG during phase
2. The beneficial outcome of the HP-IF diet may have clinical
significance as studies have shown arterial stiffness to have a
strong predictive value for cardiovascular events and all-cause
mortality (Vlachopoulos et al., 2010). In accordance with our
results, a study which examined patients with atherosclerotic
disease found that the augmentation index was significantly
correlated with both systolic BP and diastolic BP (Nürnberger
et al., 2002). PWVao, another index of arterial stiffness, increases
as a result of hypertension, atherosclerosis, or aging (Willum-
Hansen et al., 2006). Research has shown that PWVao is a
useful biomarker that can be successfully used to predict future
cardiovascular risk in patients (Ben-Shlomo et al., 2014). Our
findings are consistent with other studies showing that WL is
associated with improved PWVao (Wildman et al., 2005; Barinas-
Mitchell et al., 2006; Rider et al., 2010). Moreover, after the 1-year
follow up, there is a lower PWVao over time in the HP-IF group
as compared to the HH group, which relapsed to higher PWVao
values.
Several significant strengths characterize the present study.
First, there were two separate phases, WL and WL-M, with
two different baselines which allowed for comparison between
and within both interventions. Second, we diligently monitored
the physical activity level and diet of all participants through
both Phase 1 and Phase 2. On the other hand, the study also
had some limitations. The age range of the cohort crosses
over several reproductive stages of women (i.e., premenopausal,
perimenopausal, and postmenopausal), which could affect the
results. As is often the case in long-term human studies, the
total number of our participants in phase 2 was less than
that of phase 1 due to factors such as scheduling conflicts
and non-compliance of subjects. Presumably, participants who
finished the second phase were more motivated and committed
to the study than those who dropped out. Therefore, we
were unable to collect some follow-up data from drop outs,
potentially increasing the possibility of false positive results.
However, significant differences in baseline measurements did
not exist between groups, meaning that the dropout and
non-compliance did not produce systematic differences in
the individuals in each group. The intensity of our dietary
intervention may have been more stringent compared to other
standard dietary interventions. As a result, future studies may
need to be directed to a more practical protocol modified from
current plans.
PERSPECTIVE AND SIGNIFICANCE
In summary, a 12-week HP-IF-LC diet effectively improved BMI,
lowered cholesterol, favorably altered cardiovascular variables,
and reduced resting HR and BP. A novel finding is that a 1-year
HP-IF intervention minimizes weight regain and improves BMI,
leading to enhanced cardiovascular parameters. A comparison
between this diet and other WL and WL-M trials should be
performed in future studies, especially given that the HP-IF
diet appears to be “advantageous” in maintaining the long-term
health benefits from initial WL. A comparison WL group would
be valuable in informing us whether the HP-IF-LC diet results
in better metabolic and vascular outcomes than other traditional
WL diets. Researchers should investigate the fasting glucose
and HbA1C levels of the subjects, as diabetic and pre-diabetic
subjects are prone to cardiovascular disease. In future studies,
we will determine the exact effect of feedings during HP-IF-LC
on gastrointestinal tract function, postprandial thermogenesis,
RMR, nitrogen balance and glycosuria as compared to other
diets. Furthermore, as previous studies have confirmed the
involvement of reactive oxygen species in multiple CVD (Zuo
et al., 2011; Zhu and Zuo, 2013), assessing the potential
effects of different diets on the redox balance in the body
may be an area of interest for future dietary studies at the
molecular level. Further identification of an optimal role of
cardiac preconditioning regimens and resistance training may be
necessary as these methods may likely modulate lean body mass
and muscle strength during WL (Zuo et al., 2013; Ataee et al.,
2014).
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